Colon adenocarcinoma (COAD) is one of the most common malignancies, and its metastatic lesions are the leading cause of death in COAD patients. PANoptosis is a recently identified pathway for programmed cell death implicated in developing COAD. Long non-coding RNAs (lncRNAs) are key regulators of cancer occurrence and progress. Although their function has captured much attention in COAD, the relationship between COAD metastasis-associated lncRNA expression and PANoptosis remains elusive. Therefore, this study aimed to explore the potential regulatory roles of metastasis- and PANoptosis-associated lncRNAs in COAD. Nine lncRNAs associated with metastasis and PANoptosis in COAD were identified from The Cancer Genome Atlas (TCGA) and GEO databases. Their functions were analyzed by multiple bioinformatics methods, and the lncRNA-miRNA-mRNA network was constructed. Multivariate Cox analysis identified one lncRNA (SNHG7) significantly related to COAD prognosis. Subsequent analyses showed its expression correlated with tumor stage and lymph node metastasis. Moreover, drug sensitivity analysis and in vitro experiments suggest that lncRNA SNHG7 contributes to drug resistance in COAD. In summary, lncRNA SNHG7 is a potential target for diagnosing and treating COAD and plays a crucial role in regulating apoptosis, metastasis, and drug resistance in COAD.

Keywords: COAD, PANoptosis, lncRNA, metastasis, drug resistance

Abbreviations: CRC, colorectal cancer; COAD, colon adenocarcinoma; lncRNA, long noncoding RNA; cellRNA, competitive endogenous RNA; miRNA, microRNA; TCGA, the Cancer Genome Atlas; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; ssGSEA, Single-sample gene set enrichment analysis; CNV, copy number variation; IC50, 50% inhibition concentration.
INTRODUCTION

Colorectal cancer (CRC) is one of the most widespread malignancies, having the third highest incidence and second highest mortality rate among 36 cancers reported by GLOBOCAN 2020 (1). It is particularly common in developed countries, and unfortunately, its incidence is slowly increasing (2). Colon adenocarcinoma (COAD) is the most common subtype of CRC, and its diagnosis and treatment have seen recent rapid development. However, since metastatic cancer is one of the leading causes of death for COAD patients, their 5-year survival rate remains unsatisfactory (3). Thus, identifying potential therapeutic targets and reliable prognostic biomarkers associated with tumor metastasis is crucial, as they may contribute to the timely diagnosis and precise treatment of COAD patients.

Most cancer cells can escape apoptosis, resulting in uncontrolled proliferation (4). Furthermore, they can become resistant to chemotherapeutic agents through mutated apoptotic programs (5, 6). As a result, understanding novel programmed cell death pathways is particularly essential for combating drug resistance. PANoptosis is an inflammatory programmed cell death dependent on the PANoptosome complex (7). It contains molecules essential for pyroptosis, apoptosis, and necroptosis that activate different cell death pathways (8). Therefore, even when other programmed cell death pathways are inhibited or mutated, PANoptosis can provide an alternative pathway to kill cancer cells and reduce the risk of acquiring drug resistance. Interferon regulatory factor 1 prevents CRC development by regulating PANoptosis (9). In addition, adenosine deaminase acting on RNA 1 inhibits ZBP1-mediated PANoptosis to promote CRC development (10). These findings suggest that PANoptosis is especially important for the progression of COAD, and identifying effective PANoptosis-associated biomarkers in COAD is paramount.

Long non-coding RNAs (lncRNAs) are generally defined as transcripts longer than 200 nucleotides that regulate cancer development and progression (11). They usually act as a competitive endogenous RNA (ceRNA) that regulates the ability of microRNAs (miRNAs) to inhibit target mRNA from translating into proteins (12, 13). Increasing evidence supports that lncRNAs participate in the progression of COAD, including cell proliferation, apoptosis, metastasis, and invasion (14). Few studies, however, have addressed the role of PANoptosis-associated lncRNAs in COAD. Thus, elucidating their role in COAD may improve our understanding of how it develops and help us find new treatment strategies against it.

In this study, The Cancer Genome Atlas (TCGA) and GEO databases were used to identify differential lncRNAs associated with metastasis and PANoptosis in COAD. Differentially expressed lncRNAs were used to construct lncRNA-miRNA-mRNA network, and the functional and prognostic significance of the differentially expressed lncRNAs was further investigated by multiple bioinformatics analyses. In addition, we also analyzed the correlation between the expression of lncRNA SNHG7 in COAD and drug sensitivity. Finally, in vitro experiments demonstrated that lncRNA SNHG7 is involved in the progression of COAD. Our study provides a theoretical framework for identifying new therapeutic targets and prognostic biomarkers for COAD.

MATERIALS AND METHODS

Data Collection

Transcriptomic and clinical data for COAD were retrieved from the TCGA database (https://portal.gdc.cancer.gov). Only samples of patients with complete clinical information were included in the study. Subsequent analyses were performed on 439 COAD and 39 adjacent normal samples. Table 1 shows COAD patients’ characteristics and clinical data from TCGA. Metastasis-associated colon cancer genes were obtained from the GSE89393 transcriptome dataset from the GEO database (https://www.ncbi.nlm.nih.gov/geo/). Screening the TCGA-COAD and GSE89393 datasets for differentially expressed genes was done using the limma package in R with the screening criteria [Log, FC] ≥ 0.5 and P < 0.05 (Supplementary Tables 1 and 2). Previous studies were used to narrow the gene list and extract 14 PANoptosis-associated genes, which are mainly PANoptosome components (15). PANoptosis-associated lncRNAs were identified according to the criterium where the absolute value of Pearson’s correlation coefficient is |R| > 0.3 and significance is P < 0.05 (Supplementary Table 3 and Figure 1).

Screening PANoptosis- and Metastasis-Associated IncRNAs in Colon Adenocarcinoma

The above datasets were analyzed using the VennDiagram R package to identify lncRNA candidates. Heatmap showing the expression of 9 candidate lncRNAs in COAD and adjacent normal samples was generated with the Pheatmap R package. The R package ggplot2 was used to describe the correlation between the candidate lncRNAs and PANoptosis-associated genes. Sankey diagrams drawn by the “ggalluvial” R package were used to visualize the link between the lncRNA, PANoptosis-associated genes, and COAD prognosis.

Constructing the lncRNA-miRNA-mRNA Network

MicroRNA targets bound to PANoptosis- and metastasis-associated lncRNAs were predicted with the lncBase Predicted v.2 database (https://dianalab.e-ce.uth.gr/tools). Subsequently, the miRDB database (http://mirdb.org/index.html) was used to predict miRNA targets of the identified miRNAs. Pearson correlation analysis where P < 0.05 was considered statistically significant was applied to predict miRNA and mRNA targets that co-express with lncRNAs. The lncRNA-miRNA-mRNA network was constructed and visualized using Cytoscape 3.9.0 software.

Functional Enrichment Analysis of mRNAs in the ceRNA Network

Functional enrichment analysis was performed on 356 mRNAs co-expressed with lncRNAs in the lncRNA-miRNA-mRNA network.
network. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted with the R package clusterProfiler.

### Immune Analysis of Candidate PANoptosis- and Metastasis-Associated IncRNAs

Single-sample gene set enrichment analysis (ssGSEA) in the R package GSVA was done to assess the association of candidate lncRNAs with 9 immune cells and immune cell enrichment scores for high and low lncRNA expression groups. The R package ESTIMATE was used to calculate the patients’ ESTIMATE, immune, and stromal scores to assess cellular components.

### Prognostic and Expression Analysis of lncRNA SNHG7 High- and Low-Risk Groups

Multivariate Cox regression analysis was used to explore the relationship between the candidate lncRNAs and the prognosis in COAD patients. We discovered a prognosis-related lncRNA (SNHG7) with a \( P < 0.05 \) criterium. Subsequently, the Kaplan-Meier survival curve for lncRNA SNHG7 high- and low-risk groups was plotted.

#### Table 1: Characteristics of TCGA-COAD database.

| Characteristics | Tumor(N=439) | Adjacent normal(N=39) | Total(N=478) | pvalue | FDR |
|-----------------|--------------|------------------------|--------------|--------|-----|
| Age             |              |                        |              | 0.3    | 1   |
| <65             | 167(37.94%)  | 11(2.63%)              | 178(37.94%)  |        |     |
| ≥65             | 272(56.90%)  | 28(5.86%)              | 300(62.76%)  |        |     |
| Gender          |              |                        |              | 1      | 1   |
| FEMALE          | 210(43.93%)  | 19(3.97%)              | 229(47.91%)  |        |     |
| MALE            | 229(47.91%)  | 20(4.18%)              | 249(52.09%)  |        |     |
| T stage         |              |                        |              | 0.44   | 1   |
| T1              | 91(20.38%)   | 0(0.00%)               | 91(18.71%)   |        |     |
| T2              | 74(16.53%)   | 4(0.84%)               | 78(16.32%)   |        |     |
| T3              | 301(62.97%)  | 29(6.07%)              | 330(69.04%)  |        |     |
| T4              | 28(5.86%)    | 5(1.05%)               | 33(6.90%)    |        |     |
| T4a             | 18(3.77%)    | 0(0.00%)               | 18(3.77%)    |        |     |
| T4b             | 8(1.67%)     | 1(0.21%)               | 9(1.88%)     |        |     |
| T5a             | 1(0.21%)     | 0(0.00%)               | 1(0.21%)     |        |     |
| N stage         |              |                        |              | 0.88   |     |
| N0              | 256(53.56%)  | 27(5.65%)              | 283(59.21%)  |        |     |
| N1              | 71(15.48%)   | 51(1.05%)              | 76(15.90%)   |        |     |
| N1a             | 15(3.26%)    | 10(2.11%)              | 25(5.10%)    |        |     |
| N1b             | 15(3.26%)    | 0(0.00%)               | 15(3.15%)    |        |     |
| N1c             | 2(0.42%)     | 0(0.00%)               | 2(0.42%)     |        |     |
| N2              | 61(12.76%)   | 51(1.05%)              | 66(13.81%)   |        |     |
| N2a             | 8(1.67%)     | 0(0.00%)               | 8(1.67%)     |        |     |
| N2b             | 11(2.30%)    | 10(2.11%)              | 12(2.51%)    |        |     |
| M stage         |              |                        |              | 0.66   | 1   |
| M0              | 328(68.62%)  | 27(5.65%)              | 355(74.27%)  |        |     |
| M1              | 52(10.88%)   | 7(1.46%)               | 59(12.34%)   |        |     |
| M1a             | 9(1.88%)     | 0(0.00%)               | 9(1.88%)     |        |     |
| M1b             | 30(6.30%)    | 0(0.00%)               | 30(6.30%)    |        |     |
| M2              | 47(9.83%)    | 5(1.05%)               | 52(10.88%)   |        |     |
| Pathologic stage|              |                        |              | 0.0099 | 0.07|
| Stage I         | 73(15.27%)   | 40(8.44%)              | 77(16.11%)   |        |     |
| Stage IA        | 1(0.21%)     | 0(0.00%)               | 1(0.21%)     |        |     |
| Stage II        | 29(6.07%)    | 11(2.30%)              | 40(8.37%)    |        |     |
| Stage IIa       | 24(5.10%)    | 10(2.11%)              | 44(9.21%)    |        |     |
| Stage IIb       | 9(1.88%)     | 0(0.00%)               | 9(1.88%)     |        |     |
| Stage IIIC      | 10(2.11%)    | 0(0.00%)               | 10(2.11%)    |        |     |
| Stage III       | 20(4.18%)    | 20(4.22%)              | 22(4.60%)    |        |     |
| Stage IIIA      | 8(1.67%)     | 0(0.00%)               | 8(1.67%)     |        |     |
| Stage IIIB      | 59(12.34%)   | 40(8.44%)              | 69(13.81%)   |        |     |
| Stage IIIIC     | 41(8.58%)    | 10(2.11%)              | 51(10.88%)   |        |     |
| Stage IV        | 45(9.41%)    | 6(1.26%)               | 51(10.88%)   |        |     |
| Stage IVa       | 17(3.65%)    | 10(2.11%)              | 18(3.77%)    |        |     |
| Stage IVB       | 2(0.42%)     | 0(0.00%)               | 2(0.42%)     |        |     |
| Survival status |              |                        |              | 0.39   |     |
| Alive           | 347(72.59%)  | 28(5.86%)              | 375(78.45%)  |        |     |
| Dead            | 92(19.25%)   | 11(2.30%)              | 103(21.55%)  |        |     |
groups was generated using the R package survival. The UALCAN database (http://ualcan.path.uab.edu/) was utilized to create IncRNA SNHG7 expression box plots based on the patients’ sample types (Normal vs. Primary tumor), cancer stages (Normal vs. Stages I, II, III, and IV), and metastatic status (Normal vs. N0, N1, and N2).

**Mutational Analysis of SNHG7 in Colon Adenocarcinoma**

The copy number variation (CNV) distribution of IncRNA SNHG7 in COAD tumor samples was determined with the Gene Set Cancer Analysis platform (http://bioinfo.life.hust.edu.cn/GSCA/#/). This platform was also utilized to visualize the correlation between SNHG7 CNV and expression in COAD and conclude the overall survival probability of three CNV types (Amplification, Deletion, and Wild type) for SNHG7 in COAD.

**Drug Sensitivity Analysis of SNHG7 in Colon Adenocarcinoma**

Drug datasets were obtained from the CellMiner database (https://discover.nci.nih.gov/cellminer/home.do). The association of IncRNA SNHG7 expression with the drugs was analyzed by creating a scatter plot with the R package ggplot2. Significant associations were defined with $P < 0.05$. 

![Workflow Diagram](image-url)
Cell Culture and Plasmids
Human colorectal carcinoma cell line HCT116 was derived from the American-Type Culture Collection (ATCC). The cells were cultured in Dulbecco’s modified Eagle’s medium (Gibco, China) supplemented with 10% fetal bovine serum (Biological Industries, Israel) and maintained at 37°C with 5% CO₂.

Lentiviral vector overexpressing IncRNA SNHG7 was generated by subcloning the SNHG7 cDNA sequence into the pLVX-EF1α-IRES-Puro plasmid (Clontech, Mountain View, CA, USA). Plasmid transfection was performed using ExFect Transfection Reagent (Vazyme, China) following the manufacturer’s instructions. The viral solution was collected to infect HCT116 cells, and colonies stably overexpressing SNHG7 were selected on puromycin.

Reverse Transcription Quantitative Real-Time PCR
Total RNA was extracted from HCT116 cells using TRizol reagent (Vazyme, China) with the manufacturer’s instructions. Total RNA was reverse transcribed into cDNA using a reverse transcription kit (Vazyme, China). Quantitative PCR assay was performed using MonAmp ChemoHS qPCR Mix (Monad, China). The primer sequences (F 5′-TTGCTGGCGTCTCCTGTTAAAT-3′, R 5′-GGAAGTC CATCACAGGCGAA-3′) for SNHG7 quantitation were taken from the literature (16).

CCK-8 Assay
HCT116 cells stably overexpressing SNHG7 and controls were inoculated at a density of 1×10⁴ cells/ml into 96-well plates at 100 μl per well. After the cells fully adhered to the wall, their viability was measured at 0, 24, 48, and 72 h. Ten microliters of CCK-8 reagent (Vazyme, China) was added per well, and cells were incubated for 2 h at 37°C. The absorbance at 450 nm was measured using a Synergy 2 enzyme-labeling instrument (BioTek, USA). Finally, cell proliferation curves were plotted using GraphPad Prism (v 9.1.0).

Colony Formation Assay
Approximately 100 control cells or HCT116 cells stably overexpressing SNHG7 were inoculated in 6-well plates and cultured for 2 weeks. The cells were fixed in 10% methanol for 15 min and stained with 0.1% crystal violet for 20 min. The number of visibly stained colonies was determined using ImageJ software (v 1.51, National Institutes of Health, USA).

Cell Viability Assay
HCT116 cells were seeded into 96-well plates at a density of 2,000 cells/well. After 24 h incubation, the cells were treated with irinotecan at increasing concentrations for 72 h: 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, and 100 μM. Ten microliters per well of CCK-8 reagent (Vazyme, China) was added to the cells, and they were incubated for 2 h at 37°C. The absorbance at 450 nm was measured using a Synergy 2 enzyme-labeling instrument (BioTek, USA). Finally, graphing was performed using GraphPad Prism (v 9.1.0) to obtain IC50 values of irinotecan in HCT116 cells.

Statistical Analysis
Data were given as mean ± standard deviation. The Student’s t-test analyzed differences between groups. The correlation between the two variables was evaluated with Pearson’s correlation coefficient. Multivariate Cox regression analysis was performed to determine the prognostic indicators of overall survival. Data analysis was done in R (v 4.1.2) with statistical significance considered at P < 0.05.

RESULTS
Identifying Metastasis-Associated and PANoptosis-Associated IncRNAs in Colon Adenocarcinoma
The workflow diagram of the study is shown in Figure 1. We retrieved transcriptome profiles of 439 COAD and 39 adjacent normal samples from the TCGA database and metastatic colon cancer from the GEO database (dataset GSE89393). The metastasis-associated IncRNAs were obtained from the GSE89393 dataset. We screened the TCGA-COAD and GSE89393 datasets for differentially expressed genes with the R package limma and the screening criteria [Log (FC)] ≥ 0.5, P < 0.05. Reviewing the literature, we narrowed the list and identified 14 PANoptosis-related genes: ZBP1, NLRP3, RIPK1, RIPK3, CASP1, CASP6, CASP8, PYCARD, FADD, MAP3K7, TNFAIP3, RNF31, RBCK1, and PSTPIP2 (15). Next, using the criteria where [R] > 0.3 and P < 0.05, we performed a single-gene correlation analysis of the 14 genes to determine PANoptosis-associated IncRNAs. We found 9 IncRNAs (MIR22HG, SFTA1P, SNHG6, SNHG11, FAM222A-AS1, RHPN1-AS1, SNHG1, SNHG16, and SNHG7) present in all 3 groups (Figure 2A).

The expression levels of these overlapping IncRNAs in COAD and adjacent normal samples were presented as a heatmap (Figure 2B). Among the overlapping IncRNAs, MIR22HG and SFTA1P had lower expression in tumors than in normal tissue. By contrast, SNHG6, SNHG11, FAM222A-AS1, RHPN1-AS1, SNHG1, SNHG16, and SNHG7 were highly expressed in tumors versus normal tissue. The correlation heatmap showed that the 9 candidates were closely related to PANoptosis-related miRNAs (Figure 2C). Furthermore, a Sankey diagram visualized the degree of correlation between PANoptosis-related miRNAs and the 9 candidate IncRNAs and demonstrated the relationship between them and the prognosis of COAD patients (Figure 2D).

Constructing the IncRNA-miRNA-mRNA Network
We constructed a lncRNA-miRNA-mRNA network (Figure 3) to explore the potential roles of the candidate IncRNAs in PANoptosis and COAD metastasis. Using the IncBase Predicted v.2 database, we predicted miRNA targets that interact with the candidate IncRNAs and screened out miRNAs co-expressed with IncRNAs in COAD ([R] > 0.3, P < 0.05). Subsequently, we identified the target miRNAs by taking the intersection between the two miRNA groups. Similarly, we used the miRDB database to assess mRNA targets of the miRNAs.
and identify the intersection with the mRNAs co-expressed with lncRNAs in COAD. Finally, we detected 6 lncRNAs, 32 miRNAs, and 356 mRNAs (Table 2) and visualized this lncRNA-miRNA-mRNA network with Cytoscape software (only the top ten mRNAs correlated with lncRNAs) (Figure 3).

**Functional Enrichment Analysis of lncRNA-related mRNAs**

To explore the biological functions and signal transduction pathways of the candidate lncRNAs, we performed GO and KEGG analysis on 356 lncRNA-related mRNAs in the lncRNA-miRNA-mRNA network. GO analysis showed these lncRNA-related mRNAs were primarily associated with different significant GO terms: regulation of mRNA metabolic process, transferase complex, transferring phosphorus-containing groups, and protein serine/threonine kinase activity (Figures 4A–C). The pathway enrichment analysis revealed that mRNAs were mainly enriched in tumors and associated with cellular senescence (Figures 4D, E).

**Immune Analysis of Candidate lncRNA**

PANoptosis plays a crucial role in developing the tumor immune microenvironment (15). We used ssGSEA method to elucidate the correlation of candidate lncRNA expression with immune cell infiltration in COAD and define immune cell enrichment scores in high and low lncRNA expression groups. The data showed a correlation between candidate lncRNA expression and various tumor-infiltrating cells. For instance, lncRNAs MIR22HG and SFTA1P significantly positively correlated with macrophages, neutrophils, dendritic cells, and mast cells, whereas the remaining seven lncRNAs negatively correlated with most tumor-infiltrating cells, including B lymphocyte (Figure 5A and Supplementary Figure 1A). Moreover, there were multiple immune cell enrichment differences between the high and low lncRNA expression groups. For example, tumor-killing immune cells in the high expression group of SNHG16, SNHG6, SNHG11, FAM222A-AS1, RHPN1-AS1, SNHG1, and SNHG7 were significantly lower than those in the low (Figure 5B and Supplementary Figure 1B). We also used ESTIMATE, immune, and stromal scores to evaluate the tumor immune microenvironment in COAD. All 3 scores of the high expression group of SNHG6, SNHG11, FAM222A-AS1, RHPN1-AS1, SNHG1, and SNHG7 were significantly lower than those of the low. By contrast, the scores of the low expression group of MIR22HG and SFTA1P were lower than those of the high (Figure 5C and Supplementary Figure 1C).
Survival, Expression, and Mutational Analysis of SNHG7 in COAD

To explore the relationship of the candidate lncRNAs with patient prognosis, we used multivariate Cox regression analysis to identified one prognostic lncRNA (SNHG7) associated with PANoptosis and COAD metastasis (Figure 6A). It also had a significantly poor prognosis in the high-risk group compared with the low (Figure 6B). To further confirm the relationship of lncRNA SNHG7 with metastasis and prognosis, we analyzed its expression in different groups. We found it gradually increased with higher tumor stage and increased lymph node metastasis (Figures 6C–E). Mutational analysis revealed that amplification is the leading mutation in the SNHG7 gene (Figure 6F). Moreover, expression levels of lncRNA SNHG7 positively correlated with the degree of CNV in COAD (Figure 6G). Finally, overall survival was significantly lower in patients with predominantly SNHG7 amplification mutations (Figure 6H). These results indicate high expression of PANoptosis-associated lncRNA SNHG7 predicts poor prognosis in COAD.

SNHG7 Contributes to COAD Cell Proliferation and Irinotecan Resistance

We performed in vitro experiments to investigate whether lncRNA SNHG7 plays a role in the progression of COAD. SNHG7 expression is relatively low in the HCT116 cell line (16, 17). Thus, we overexpressed SNHG7 in HCT116 cells and verified its overexpression with RT-qPCR (Supplementary Figure 2A). CCK-8 and clone formation assays showed that SNHG7 overexpression promotes proliferation of HCT116 cells (Supplementary Figures 2B and C), confirming lncRNA SNHG7 stimulates COAD progression. Since tumor metastasis and anti-apoptosis often accompany the development of drug resistance (18, 19), we explored whether SNHG7 is associated with drug resistance. Drug datasets were obtained from the CellMiner database, and the association of SNHG7 expression with more than 20,000 compounds was analyzed by creating a scatter plot with the R package ggplot2. Figure 7 and Table 3 show the relationship between drug sensitivity and SNHG7 expression for 25 compounds correlating most closely with SNHG7.
expression. Overall, drug sensitivity analysis showed that the expression of SNHG7 positively correlated with 50% inhibition concentration (IC50) of most drugs. Irinotecan is a therapeutic effect of chemotherapeutic drugs. Therefore, SNHG7 expression of lncRNAs affects the proliferation, apoptosis, drug resistance, migration, and invasion of COAD cells (22–27). How
FIGURE 4 | Functional and Pathway Enrichment Analysis of mRNAs in the lncRNA-miRNA-mRNA Network. (A–C) The mRNAs associate with three GO categories: biological process, cellular component, and molecular function. The most significant GO terms for lncRNA-related mRNAs are regulation of mRNA metabolic process, transferase complex, transferring phosphorus-containing groups, and protein serine/threonine kinase activity. (D, E) KEGG pathway analysis reveals mRNA-enriched associated signaling pathways. The most enriched KEGG pathway for lncRNA-associated mRNAs is the cancer.

FIGURE 5 | Immune Infiltration Analysis of Candidate PANoptosis- and Metastasis-Related lncRNAs. (A) Correlation of candidate lncRNAs with different tumor-infiltrating immune cells. (B) Immune cell infiltration in high and low lncRNA expression groups. (C) Comparison of ESTIMATE, immune, and stromal scores in candidate lncRNA high and low expression groups. *P < 0.05; **P < 0.01; ***P < 0.001; ns P > 0.05 (ns, not significant).
and lncRNAs to uncover the specific regulatory roles of PANoptosis- and COAD metastasis-related lncRNAs in COAD.

Our study identified 9 lncRNAs related to PANoptosis and COAD metastasis through a comprehensive analysis of publicly available transcriptome datasets. Subsequently, we constructed a ceRNA network of candidate lncRNAs in COAD. To better grasp the molecular functions of aberrantly expressed lncRNAs, we analyzed 356 mRNAs associated with lncRNAs in the network. Pathway enrichment analyses showed that most network pathways were enriched in cancer and associated with tumor proliferation, apoptosis, drug resistance, invasion, and migration, including the Hippo and MAPK signaling (29–31). Immune cells in the tumor immune microenvironment play key roles in tumor control and immunity. PANoptosis is also associated with the tumor microenvironment (6). Immune infiltration analysis uncovered that 9 lncRNAs were significantly associated with immune infiltration. The low expression group of SNHG16, SNHG6, SNHG11, FAM222A-AS1, RHPN1-AS1, SNHG1, and SNHG7 was accompanied by more immune cell infiltration, further supporting that PANoptosis plays a crucial role in the tumor immune microenvironment. LncRNAs SNHG16 and SNHG1 have been proven to regulate the cancer immune microenvironment. Ni et al. found that SNHG16 activates the TGF-β1/SMAD5 pathway by targeting miR-16-5p, causing the transformation of gd1 T cells into the CD73+ immunosuppressive subtype (32). Likewise, SNHG1 participates in immune escape by regulating T cells in renal cell carcinoma and breast cancer (33, 34).

Multivariate Cox regression analysis showed that LncRNA SNHG7 considerably correlated with the prognosis of COAD patients, and its high expression significantly reduced their survival rate. The expression of SNHG7 also significantly positively correlated with the tumor stage and lymph node metastasis in COAD. We demonstrated that SNHG7 promotes COAD progression by enhancing cell proliferation. And previous experiments have fully proved that SNHG7 can also affect tumor cell apoptosis, invasion and migration in COAD. For example, SNHG7 binds miR-216b and promotes CRC proliferation and liver metastasis by upregulating GALNT1 (17). Inhibiting K-ras/ERK/cyclin D1 pathway by silencing SNHG7 reduces CRC proliferation and promotes apoptosis (35). In addition, SNHG7 promotes tumor chemo-resistance in various tumors. For instance, exosome-mediated transfer of SNHG7 enhances docetaxel resistance in lung adenocarcinoma (36). Similarly, it increases trastuzumab resistance in breast cancer cells via regulating miR-186 (37). Our drug sensitivity analysis found a correlation between the expression of SNHG7 and the first-line chemotherapy drug irinotecan,
**TABLE 3 | Drug Sensitivity Analysis of SNHG7.**

| Gene         | Drug               | cor      | pvalue     |
|--------------|--------------------|----------|------------|
| SNHG7        | Belinostat         | 0.475150756 | 0.000124941 |
| SNHG7        | Vorinostat         | 0.458034671 | 0.000233285 |
| SNHG7        | ST-3595            | 0.44524744  | 0.000364234 |
| SNHG7        | LMP776             | 0.409005076 | 0.00117581  |
| SNHG7        | Methylprednisolone | 0.401629543 | 0.001469495 |
| SNHG7        | Pluripotin         | -0.396574183| 0.001707192 |
| SNHG7        | Cytarabine         | 0.394164857 | 0.002103212 |
| SNHG7        | Hydroxyurea        | 0.398341558 | 0.002168588 |
| SNHG7        | Chelerythrine      | 0.374746552 | 0.00317741  |
| SNHG7        | Karenitecin        | 0.370615145 | 0.003557304 |
| SNHG7        | Ifosfamide         | 0.368587346 | 0.003758079 |
| SNHG7        | Raltitrexed        | 0.36798446  | 0.00385958  |
| SNHG7        | Asparaginase       | 0.364779387 | 0.004162362 |
| SNHG7        | Ribavirin          | 0.35637975  | 0.00519255  |
| SNHG7        | Nelarabine         | 0.350020389 | 0.006115555 |
| SNHG7        | Triethylenemelamine| 0.349079912 | 0.006263608 |
| SNHG7        | Fluphenazine       | 0.346037147 | 0.006764353 |
| SNHG7        | Thiotepa           | 0.333471406 | 0.00922025  |
| SNHG7        | Cladribine         | 0.332836742 | 0.009266744 |
| SNHG7        | Irinotecan         | 0.330403599 | 0.009282801 |
| SNHG7        | Dasatinib          | -0.32892077 | 0.010416805 |
| SNHG7        | Pipobroman         | 0.328083936 | 0.010493415 |
| SNHG7        | Gemcitabine        | 0.327504385 | 0.010638828 |
| SNHG7        | LMP-400            | 0.327348563 | 0.010678221 |
typically given for treating metastatic COAD. High expression of SNHG7 enhances tumor resistance to irinotecan. To validate, we examined IC50 values of irinotecan in COAD cell lines overexpressing SNHG7 and control cells. Indeed, higher IC50 values in the overexpressing cells versus the control were consistent with our assumption that SNHG7 contributes to irinotecan resistance in COAD.

Although our study indicates that PANoptosis- and COAD metastasis-related lncRNA SNHG7 has decisive regulatory roles in COAD, it has limitations. The sample size is limited without any supporting clinical samples, which may cause deviations. Moreover, the underlying mechanism by which SNHG7 promotes COAD progression requires further investigation.

CONCLUSION

In conclusion, we carried out a comprehensive and systematic bioinformatics analysis of COAD patient samples and demonstrated that the occurrence and progression of COAD are closely related to PANoptosis. We also identified PANoptosis-related lncRNA SNHG7 associated with COAD metastasis, chemoresistance, and prognosis. Therefore, we suggest lncRNA SNHG7 as a potential prognostic biomarker and therapeutic target for COAD.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71 (3):209–49. doi: 10.3322/caac.21660
2. Li J. Digestive Cancer Incidence and Mortality Among Young Adults Worldwide in 2020: A Population-Based Study. World J Gastrointest Oncol (2022) 14(1):278–94. doi: 10.4251/wjgio.14.278
3. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sunn JI, Roelens PG, et al. Colorectal Cancer. Nat Rev Dis Primers (2015) 1:15065. doi: 10.1038/nrdp.2015.65
4. Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, et al. Broad Targeting of Resistance to Apoptosis in Cancer. Semin Cancer Biol (2015) 35 Suppl 78–103. doi: 10.1016/j.semcancer.2015.03.001
5. Malireddi RKS, Tweedell RE, Kanneganti TD. Panoptosis Components, Regulation, and Implications. Aging (Albany NY) (2020) 12(12):11163–4. doi: 10.1186/s40020-012-0352-6
6. Jiang M, Qi L, Li L, Wu Y, Song D, Li Y. Caspase-8: A Key Protein of Cross-Talk Signal Way in 'Panoptosis' in Cancer. Int J Cancer (2021) 149(7):1408–20. doi: 10.1002/ijc.33698
7. Wang Y, Kanneganti TD. From Pyroptosis, Apoptosis and Necroptosis (Panoptosis). Front Cell Infect Microbiol (2020) 10:237. doi: 10.3389/fcimb.2020.00237
8. Malireddi RKS, Tweedell RE, Kanneganti TD. Panoptosis Components, Regulation, and Implications. Aging (Albany NY) (2020) 12(12):11163–4. doi: 10.1186/s40020-012-0352-6
9. Karki R, Sharma BR, Lee E, Banoth B, Malireddi RKS, Samir P, et al. Interferon Regulatory Factor 1 regulates Panoptosis to Prevent Colorectal Cancer. JCI Insight (2020) 5(12):e136720. doi: 10.1172/jci.insight.136720
10. Karki R, Sundaram B, Sharma BR, Lee S, Malireddi RKS, Nguyen LN, et al. Adar1 restricts Zbp1-Mediated Immune Response and Panoptosis to Promote Tumorigenesis. Cell Rep (2021) 37(3):109858. doi: 10.1016/j.celrep.2021.109858
11. Huarte M. The Emerging Role of Lncrnas in Cancer. Nat Med (2015) 21 (11):1253–61. doi: 10.1038/nm.3981
12. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A Cerna Hypothesis: The Rosetta Stone of a Hidden Rna Language? Cell (2011) 146(3):353–8. doi: 10.1016/j.cell.2011.07.014
13. Zhao Y, Zhang H, Ju Q, Li X, Zheng Y. Comprehensive Analysis of Survival-Related Lncrnas, Mirnas, and Mrrnas Forming a Competing Endogenous Rna Network in Gastric Cancer. Front Genet (2021) 12:610501. doi: 10.3389/fgene.2021.610501
14. Chen S, Shen X. Long Noncoding Rnas: Functions and Mechanisms in Colon Cancer. Mol Cancer (2020) 19(1):167. doi: 10.1186/s12935-020-01287-2
15. Samir P, Malireddi RKS, Kanneganti TD. The Panoptosome: A Deadly Protein Complex Driving Pyroptosis, Apoptosis, and Necroptosis (Panoptosis). Front Cell Infect Microbiol (2020) 10:238. doi: 10.3389/fcimb.2020.00238
16. Li Y, Zeng C, Hu J, Pan Y, Shan Y, Liu B, et al. Long Non-Coding Rna-Snhg7 Acts as a Target of Mir-34a to Increase Galnt7 Level and Regulate Pi3k/Akt/Mtor Pathway in Colorectal Cancer Progression. J Hematol Oncol (2018) 11

AUTHOR CONTRIBUTIONS

YJ contributed conception, administration of this study and revised this manuscript. JH contributed equally in analysis and wrote the manuscript. SJ, LL, HH, YL, LC helped in data collection and organization. All authors have read and agreed to the final manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China [81802785 (YJ), 82100490 (LC)], the Hunan Provincial Natural Science Foundation of China [2020J5382 (YJ), 2020JJ5381 (LC)], Scientific Research Program of Hunan Provincial Health Commission [202202065445 (YJ)].

ACKNOWLEDGMENTS

We thank LC for verification of the figures and the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.888105/full#supplementary-material
17. Shan Y, Ma J, Pan Y, Hu J, Liu B, Jia L. Lncrna Snhg7 Sponges Mir-216b to Promote Proliferation and Liver Metastasis of Colorectal Cancer Through Upregulating Galnt1. *Cell Death Dis* (2018) 9(7):722. doi: 10.1038/s41419-018-0759-7

18. Norouzi S, Gorgi Valokala M, Mosaffa F, Zirak MR, Zamani P, Behravan J. Crosstalk in Cancer Resistance and Metastasis. *Crit Rev Oncol Hematol* (2018) 132:145–53. doi: 10.1016/j.critrevonc.2018.09.017

19. Kaufmann SH, Vaux DL. Alterations in the Apoptotic Machinery and Their Potential Role in Anticancer Drug Resistance. *Oncogene* (2003) 22(47):7414–30. doi: 10.1038/sj.onc.1206945

20. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential Versus Combination Chemotherapy With Cephalotaxine, Irinotecan, and Oxaliplatin in Advanced Colorectal Cancer (Cairo): A Phase III Randomised Controlled Trial. *Lancet* (2007) 370(9582):135–42. doi: 10.1016/S0140-6736(07)61086-1

21. Van Cutsem E, Cervantes A, Nordinger B, Arnold D, Group EGW. Metastatic Colorectal Cancer: Esmo Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. *Ann Oncol* (2014) 25(Suppl 3):iii1–9. doi: 10.1093/annonc/mdu260

22. Yang H, Wang S, Kang YJ, Wang C, Xu Y, Zhang Y, et al. Long Non-Coding Rna Snhg1 Predicts a Poor Prognosis and Promotes Colon Cancer Tumorigenesis. *Oncol Rep* (2018) 40(1):261–71. doi: 10.3892/or.2018.6412

23. Yue B, Cai D, Liu C, Fang C, Yan D. Linc00152 Functions as a Competing Endogenous Rna to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer. *Mol Ther* (2016) 24(12):2064–77. doi: 10.1038/mt.2016.180

24. Chen S, Bu D, Ma Y, Zhu J, Chen G, Sun L, et al. H19 Overexpression Induces Resistance to 1,25(OH)2d3 by Targeting Vdr Through Mir-675-5p in Colon Cancer Cells. *Neoplasia* (2017) 19(3):226–36. doi: 10.1016/j.neo.2016.10.007

25. Ni C, Fang QQ, Chen WZ, Jiang JX, Jiang Z, Ye J, et al. Breast Cancer-Derived Exosomes Transmit Lncrna Snhg16 to Induce Cd73+Gammadelta1 Treg Cells. *Signal Transduct Target Ther* (2020) 5(1):41. doi: 10.1038/s41392-020-0129-7

26. Tian P, Wei JX, Li J, Ren JK, Yang Jl. Lncrna Snhg1 Regulates Immune Escape of Renal Cell Carcinoma By Targeting Mir-129-3p to Activate Stat3 and Pd-L1. *Cell Biol Int* (2021) 45(7):1546–60. doi: 10.1002/cbin.11595

27. Zhang H, Zhang XY, Kang XN, Jin LJ, Wang ZY. Lncrna-Snhg7 Enhances Oxosomes Transmit Lncrna Snhg16 to Induce Cd73++Gammadelta1 Treg Cells. *Frontiers in Oncology* (2022) 12:100069. doi: 10.1016/j.fonc.2022.100069

28. McCreary JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Zhang F, et al. Roles of the Raf/Mek/Erk Pathway in Cell Growth, Malignant Transformation and Drug Resistance. *Biochim Biophys Acta* (2007) 1773 (8):1263–84. doi: 10.1016/j.bbamcr.2006.10.001

29. Misra JR, Irvine KD. The Hippo Signaling Network and Its Biological Functions. *Annu Rev Genet* (2018) 52:65–87. doi: 10.1146/annurev-genet-120417-031621

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Huang, Jiang, Liang, He, Liu, Cong and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.